Nifty500 Healthcare

Abbott India stock rallies as investors respond to strong recent earnings

Abbott India stock rallied over 5% on September 18, 2026, reaching an intraday high of INR 27,490. Investors responded to strong recent earnings, with the company reporting high single-digit revenue growth and double-digit net profit expansion in its latest quarter. The stock outperformed its sector peers, supported by positive technical indicators.

Pfizer’s Dividend Yield Is Enormous. But Is the Payout Still Growing?

Pfizer's dividend growth streak ended in January 2026, with the quarterly payout remaining at $0.43 after over a decade of increases. While the 6.20% yield is maintained and management affirmed commitment to the dividend, the pause contrasts with peers like Merck and Bristol-Myers Squibb, who recently raised theirs. This comes as Pfizer faces declining sales for Comirnaty and Paxlovid, alongside generic competition.

Diagnostic Chain Stock Rises 43% in 1 Year: What Drove It

Vijaya Diagnostic Centre Ltd's stock rose 43% in one year, driven by five consecutive quarters of margin expansion and strong financial results. The company reported a 42.7% EBITDA margin and 37.6% profit growth in the June 2026 quarter. A recent Rs 46.20 crore acquisition in Guwahati also contributed to the gains.

Narayana Hrudayalaya plans to add around 500 beds in Delhi by FY29

Narayana Hrudayalaya Ltd. plans to add approximately 500 beds in Delhi by fiscal year 2029 as part of its expansion strategy in the national capital. This addition is included in the company's projected capital expenditure program through 2029, which totals around INR 30 billion. The expansion aims to address the shortage of hospital beds in Delhi and meet the significant healthcare demand in North India.

Taro Pharmaceutical Industries stock gains on Sun Pharma merger cash offer

Taro Pharmaceutical Industries stock is gaining as a cash merger with Sun Pharmaceutical Industries is finalized. Shareholders will receive $32.25 per share as of September 17, 2026, converting equity into a fixed cash payout. This move aligns with Sun Pharma's strategy to consolidate subsidiaries and streamline its corporate structure.